Endocrinol Metab.  2018 Jun;33(2):219-227. 10.3803/EnM.2018.33.2.219.

Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis

Affiliations
  • 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. edgo@yuhs.ac
  • 2Graduate School, Yonsei University College of Medicine, Seoul, Korea.
  • 3Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea.
  • 4Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • 5Department of Medicine (Cardiology) and Radiology, University of Virginia Health System, Charlottesville, VA, USA.
  • 6Second Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic.
  • 7Vascular Surgery Unit, Department of Surgery, University of Ioannina, Ioannina, Greece.
  • 8Musashino Tokusyu Hospital, Tokyo, Japan.
  • 9Department of Biostatistics, The Catholic University of Korea, Seoul, Korea.
  • 10Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • 11Cardiovascular Research Institute and Cardiovascular Genome Center, Yonsei University College of Medicine, Seoul, Korea.

Abstract

BACKGROUND
Ezetimibe-statin combination therapy has been found to reduce low density lipoprotein cholesterol levels and the risk of major adverse cardiovascular events (MACEs) in large trials. We sought to examine the differential effect of ezetimibe on MACEs when added to statins according to the presence of diabetes.
METHODS
Randomized clinical trials with a sample size of at least 50 participants and at least 24 weeks of follow-up that compared ezetimibe-statin combination therapy with a statin- or placebo-controlled arm and reported at least one MACE, stratified by diabetes status, were included in the meta-analysis and meta-regression.
RESULTS
A total of seven trials with 28,191 enrolled patients (mean age, 63.6 years; 75.1% men; 7,298 with diabetes [25.9%]; mean follow-up, 5 years) were analysed. MACEs stratified by diabetes were obtained from the published data (two trials) or through direct contact (five trials). No significant heterogeneity was observed among studies (I 2=14.7%, P=0.293). Ezetimibe was associated with a greater reduction of MACE risk in subjects with diabetes than in those without diabetes (pooled relative risk, 0.84 vs. 0.93; P heterogeneity=0.012). In the meta-regression analysis, the presence of diabetes was associated with a greater reduction of MACE risk when ezetimibe was added to statins (β=0.87, P=0.038).
CONCLUSION
Ezetimibe-statin combination therapy was associated with greater cardiovascular benefits in patients with diabetes than in those without diabetes. Our findings suggest that ezetimibe-statin combination therapy might be a useful strategy in patients with diabetes at a residual risk of MACEs.

Keyword

Ezetimibe; Myocardial infarction; Stroke; Hydroxymethylglutaryl-CoA reductase inhibitors; Diabetes mellitus

MeSH Terms

Arm
Cholesterol, LDL
Diabetes Mellitus
Ezetimibe
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Male
Myocardial Infarction
Population Characteristics
Sample Size
Stroke
Cholesterol, LDL
Ezetimibe
Hydroxymethylglutaryl-CoA Reductase Inhibitors

Figure

  • Fig. 1 Flow diagram of the literature search to identify randomized controlled trials (RCTs) comparing the differential effect of ezetimibe combination therapy on the reduction of major adverse cardiovascular events (MACEs) according to the presence of diabetes. DM, diabetes mellitus.

  • Fig. 2 Pooled effects of ezetimibe-statin combination therapy on major adverse cardiovascular events grouped by the presence of diabetes within studies. The test for heterogeneity between subgroups was significant (A) in all studies (P=0.012) and (B) after excluding the placebo-controlled trial (SHARP) (P=0.022). RR, risk ratio; CI, confidence interval; DM, diabetes mellitus; SHARP, the Study of Heart and Renal Protection; HEAVEN, virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration study; PRECISE-IVUS, Plaque Regression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound Study; IMPROVE-IT, the Improved Reduction of Outcomes: Vytorin Efficacy International Trial.


Cited by  2 articles

2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea
Kyu Yeon Hur, Min Kyong Moon, Jong Suk Park, Soo-Kyung Kim, Seung-Hwan Lee, Jae-Seung Yun, Jong Ha Baek, Junghyun Noh, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Ye Seul Yang, Jang Won Son, Jong Han Choi, Kee Ho Song, Nam Hoon Kim, Sang Yong Kim, Jin Wha Kim, Sang Youl Rhee, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim, Chong Hwa Kim, Dae Jung Kim, SungWan Chun, Eun-Jung Rhee, Hyun Min Kim, Hyun Jung Kim, Donghyun Jee, Jae Hyun Kim, Won Seok Choi, Eun-Young Lee, Kun-Ho Yoon, Seung-Hyun Ko
Diabetes Metab J. 2021;45(4):461-481.    doi: 10.4093/dmj.2021.0156.

Triennial Report of Endocrinology and Metabolism, 2015 to 2017
Eun-Jung Rhee, Hey Yeon Jang, Won-Young Lee
Endocrinol Metab. 2018;33(2):195-201.    doi: 10.3803/EnM.2018.33.2.195.


Reference

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366:1267–1278. PMID: 16214597.
2. Cholesterol Treatment Trialists' (CTT) Collaboration. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:1670–1681. PMID: 21067804.
3. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet. 1996; 347:949–950. PMID: 8598762.
Article
4. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25 Pt B):2889–2934. PMID: 24239923.
5. ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1563–1574. PMID: 20228404.
Article
6. Park SW. Intestinal and hepatic niemann-pick c1-like 1. Diabetes Metab J. 2013; 37:240–248. PMID: 23991401.
Article
7. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002; 106:1943–1948. PMID: 12370217.
Article
8. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372:2387–2397. PMID: 26039521.
Article
9. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377:2181–2192. PMID: 21663949.
10. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMID: 19622551.
Article
11. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMID: 22008217.
Article
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557–560. PMID: 12958120.
Article
13. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150:604–612. PMID: 19414839.
Article
14. Sedgwick P. Meta-analyses: heterogeneity and subgroup analysis. BMJ. 2013; 346:f4040.
Article
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629–634. PMID: 9310563.
Article
16. West AM, Anderson JD, Meyer CH, Epstein FH, Wang H, Hagspiel KD, et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis. 2011; 218:156–162. PMID: 21570685.
Article
17. Kovarnik T, Mintz GS, Skalicka H, Kral A, Horak J, Skulec R, et al. Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study. Circ J. 2012; 76:176–183. PMID: 22076422.
18. Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, Kostara C, Gartzonika C, Bairaktari ET, et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. J Cardiovasc Pharmacol Ther. 2013; 18:5–12. PMID: 22573476.
19. Suzuki H, Watanabe Y, Kumagai H, Shuto H. Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Ther Adv Cardiovasc Dis. 2013; 7:306–315. PMID: 24280596.
Article
20. Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015; 66:495–507. PMID: 26227186.
21. Savarese G, De Ferrari GM, Rosano GM, Perrone-Filardi P. Safety and efficacy of ezetimibe: a meta-analysis. Int J Cardiol. 2015; 201:247–252. PMID: 26301648.
Article
22. Fei Y, Guyatt GH, Alexander PE, El Dib R, Siemieniuk RA, Vandvik PO, et al. Addition of Ezetimibe to statins for patients at high cardiovascular risk: systematic review of patient-important outcomes. J Eval Clin Pract. 2018; 24:222–231. PMID: 28090731.
Article
23. Battaggia A, Donzelli A, Font M, Molteni D, Galvano A. Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015; 10:e0124587. PMID: 25915909.
Article
24. Thomopoulos C, Skalis G, Michalopoulou H, Tsioufis C, Makris T. Effect of low-density lipoprotein cholesterol lowering by ezetimibe/simvastatin on outcome incidence: overview, meta-analyses, and meta-regression analyses of randomized trials. Clin Cardiol. 2015; 38:763–769. PMID: 26282344.
Article
25. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016; 37:2999–3058. PMID: 27567407.
Article
26. Committee for the Korean Guidelines for the Management of Dyslipidemia. 2015 Korean guidelines for the management of dyslipidemia: executive summary (English translation). Korean Circ J. 2016; 46:275–306. PMID: 27275165.
27. Nayor M, Vasan RS. Recent update to the US cholesterol treatment guidelines: a comparison with international guidelines. Circulation. 2016; 133:1795–1806. PMID: 27143546.
28. Ravid Z, Bendayan M, Delvin E, Sane AT, Elchebly M, Lafond J, et al. Modulation of intestinal cholesterol absorption by high glucose levels: impact on cholesterol transporters, regulatory enzymes, and transcription factors. Am J Physiol Gastrointest Liver Physiol. 2008; 295:G873–G885. PMID: 18772361.
Article
29. Lally SE, Owens D, Tomkin GH. Sitosterol and cholesterol in chylomicrons of type 2 diabetic and non-diabetic subjects: the relationship with ATP binding cassette proteins G5 and G8 and Niemann-Pick C1-like 1 mRNA. Diabetologia. 2007; 50:217–219. PMID: 17102949.
Article
30. Vaverkova H, Farnier M, Averna M, Missault L, Viigimaa M, Dong Q, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovasc Ther. 2012; 30:61–74. PMID: 20626402.
Article
31. Leiter LA, Betteridge DJ, Farnier M, Guyton JR, Lin J, Shah A, et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab. 2011; 13:615–628. PMID: 21332628.
Article
32. Koh KK, Oh PC, Sakuma I, Kim EY, Lee Y, Hayashi T, et al. Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia. Int J Cardiol. 2015; 199:126–131. PMID: 26188833.
Article
33. Tie C, Gao K, Zhang N, Zhang S, Shen J, Xie X, et al. Ezetimibe attenuates atherosclerosis associated with lipid reduction and inflammation inhibition. PLoS One. 2015; 10:e0142430. PMID: 26555472.
Article
34. Patel SB. Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways. Curr Cardiol Rep. 2004; 6:439–442. PMID: 15485605.
Article
35. Qin L, Yang YB, Yang YX, Gong YZ, Li XL, Li GY, et al. Inhibition of smooth muscle cell proliferation by ezetimibe via the cyclin D1-MAPK pathway. J Pharmacol Sci. 2014; 125:283–291. PMID: 25048018.
Article
36. Hussein O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol. 2008; 65:637–645. PMID: 18241285.
Article
37. Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008; 359:1357–1366. PMID: 18765432.
Article
38. Drazen JM, D'Agostino RB, Ware JH, Morrissey S, Curfman GD. Ezetimibe and cancer: an uncertain association. N Engl J Med. 2008; 359:1398–1399. PMID: 18765434.
Full Text Links
  • ENM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr